Study of Sacituzumab Govitecan-hziy in Metastatic Urothelial Cancer
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of sacituzumab
govitecan-hziy in participants with metastatic urothelial cancer (mUC).